arrow
C

Christopher Pieczonka

university of helsinki
H指数:16
被引数:1,827

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial

使用恩扎卢胺联合醋酸亮丙瑞林治疗高风险生化复发的前列腺癌:EMBARK试验的次要终点

2026-05-016
PRE
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels

膀胱癌治疗中使用留置性膀胱内药物释放系统的不良反应管理及操作最佳实践:专家小组建议

2026-01-010
PRE
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

DARolutamide观察性(DAROL)研究:非转移性去势抵抗性前列腺癌患者的预先设定第三次中期分析

2025-11-010
OA
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

阿贝西利布联合阿比特龙在转移性去势抵抗性前列腺癌患者中的研究(CYCLONE 2):一项随机、双盲、安慰剂对照、Ⅲ期临床试验

2025-10-270
PRE
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

恩扎卢替尼在生化复发性前列腺癌中改善了生存率

2025-10-011
PRE
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients

利用PROCLAIM试验中的患者报告结局评估对前列腺癌患者进行普遍胚系基因检测的影响

2025-09-220
OAAI
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer

针对前列腺癌患者进行通用种系基因检测的临床报告管理建议

2024-12-013
PRE
Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial

PD-L1表达与TAR-200临床反应的相关性:SunRISe-1期IIb临床试验

2024-09-010
PRE
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
2023-11-114
OAAI
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

恩扎鲁他胺改善生化复发性前列腺癌的预后

2023-10-1984
PRE
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial

国家综合癌症网络指南在未经选择的前列腺癌患者中鉴定致病性种系变异的功效: prosunl试验

2023-10-018
OA